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The “Convention for the protection of human rights 
and dignity of human beings with regards to the ap-
plication of biology and medicine: Convention on hu-
man rights and biomedicine” [1] (hereinafter the Con-
vention) of the Council of Europe is one of the most 
authoritative reference documents on the subject of 
bioethics.
This year sees the twentieth anniversary of the adop-
tion of the Convention, which was opened for signature 
by Member States on 4th April 1997.
The Convention, which was opened for signature by 
Member States on 4th April 1997, comprises 14 chap-
ters that address the basic issues of: consent (chapter 
2), private life and right to information (chapter 3), 
human genome (chapter 4), scientific research (chap-
ter 5), organ and tissue removal from living donors for 
transplantation purposes (chapter 6), prohibition of fi-
nancial gain and disposal of a part of the human body 
(chapter 7).
Article 27 allows Member States to grant wider pro-
tection through legislation at national level: thus the 
Convention establishes the minimum indispensable 
standards.
Some of the principles affirmed in the Convention 
were subsequently supplemented by additional pro-
tocols addressing specific issues, such as: the prohibi-
tion of cloning human beings [2]; the transplantation 
of organs and tissues of human origin [3]; biomedical 
research [4]; genetic testing for health purposes [5].
The Convention was ratified in Italy by Law no.145 
of 28th March 2001, but although the law was passed 
by the Italian Parliament it has not yet been filed by 
the Italian government with the General Secretariat of 
the Council of Europe. This final step in its legislative 
procedure has been solicited by various parties, includ-
ing the Italian National Bioethics Committee, which on 
24th February 2012 adopted a “Motion to complete the 
ratification procedure of the Oviedo Convention” [6].
Although the ratification procedure is not formally 
complete, the Convention is nonetheless quoted in Ital-
ian case-law and is an important point of reference for 
jurists and bioethicists. Indeed, it is listed among the 
reference documents that inspired the “Codice di Etica 
dell’Istituto Superiore di Sanità” (Code of Ethics of the 
Italian National Institute of Health [7]). 
That the Convention contains instances of ambiguity 
is explicitly admitted in the Explanatory Report [8] and 
is borne out by the fact that Article 1 fails to provide a 
definition of a human being. The text refers both to “hu-
man beings” and to “everyone” (and in French to “être 
humain” and “toute personne”).
One of the articles most susceptible to diverging inter-
pretations is Article 21 (“Prohibition of financial gain”), 
which states that: “The human body and its parts shall 
not, as such, give rise to financial gain”. In this case, 
though, potential differences in interpretation could 
arise less from any lack of clarity in the text, which is 
unequivocal, than from the multitude and heterogene-
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ity of situations involving the use of human cells, blood, 
tissues and organs.
The procedures involved in the collection, possible 
processing, storage and use of human biological mate-
rial frequently incur considerable costs, and there is a 
need to ensure that legitimate refunds for expenses and 
the relative flows of money are not allowed to conceal 
mechanisms intended to generate any kind of financial 
gain. The principle underlying the prohibition of finan-
cial gain is intrinsically linked to the prohibition of traf-
ficking in human cells, organs or tissues.
In order to prepare a proper interpretation of Article 
21 of the Convention, the Council of Europe set up the 
Ad hoc Working Group on The prohibition of financial 
gain with the task of “preparing proposals for clarifica-
tion of key notions with a view to facilitate the imple-
mentation of the principle in Article 21 of the Oviedo 
Convention”, on which the Head of the Bioethics Unit 
of the Istituto Superiore di Sanità (ISS, Italian National 
Institute of Health), who is also co-author of the pres-
ent paper, represented Italy.
The Working Group was installed on 22nd February 
2016 and, after examining a number of legal instru-
ments and reference documents relevant to the prin-
ciple of the prohibition of financial gain and in-depth 
discussion of the issue, it produced a draft text: this was 
then discussed and amended and the final text was ad-
opted on 11th October 2016 [9].
The text was then forwarded to the Committee on 
Bioethics (DH-BIO), which conducted an editorial re-
vision on it in 2017, and subsequently adopted it on 4th 
December 2017. The guide was then sent to the Euro-
pean Committee on Organ Transplantation (CE-P-TO) 
an d the CD-P-TO and the European Committee on 
Blood Transfusion (CE-P-TS). The CD-P-TO adopted 
the guide on 11th January 2018 [9].
The ad hoc working group felt that it should focus its 
efforts on the issues surrounding donation and the pro-
hibition of financial gain in relation to the human body 
and its parts, excluding the field of research. 
The document offers “guidance on how to interpret 
the principle of the prohibition of financial gain with 
respect to the human body and its parts from living or 
deceased donors in order to define a common frame-
work for its interpretation”. It recognises that the aim of 
the principle is twofold. On the one hand it is intended 
to underscore the welfare and respect for the human 
rights of living donors, and on the other hand it aims to 
protect recipients by ensuring the safety and quality of 
the bodily materials donated.
The document also recognises that the prohibition of 
financial gain is compatible with ensuring financial neu-
trality for living donors and, therefore, that the prohibi-
tion of financial gain does not preclude:
•  “compensation of living donors for loss of earnings 
and reimbursement of any other justifiable expenses 
caused by the removal or by the related medical ex-
aminations; 
•  compensation in case of undue damage resulting 
from the removal of organs, tissues or cells”.
The document also notes that the prohibition of fi-
nancial gain does not preclude the payment of “a justifi-
able fee for medical or related technical services ren-
dered in connection with donation”. Throughout the 
document the term “reimbursement” is used in relation 
to expenses such as travel and other outlays incurred in 
connection with a donation, while the term “compensa-
tion” is used in relation to any loss of income or earn-
ings connected with a donation.
In the matter of the reimbursement of justifiable ex-
penses and compensation for loss of earnings for living 
donors the document notes that this is permitted by 
the requisite of financial neutrality for the living donor. 
When the costs incurred are of a kind for which the 
donor is able to produce receipts, such as travel tickets, 
the fact that the cost is justifiable – and therefore ac-
ceptable – is apparent.
Other costs, such as lost earnings, costs related to the 
care of dependants or to follow-up visits, are less straight-
forward to determine. The dominant principle should be 
that the act of donation should not give rise either to a 
financial loss or to a financial gain for the donor. In order 
to ensure that they are properly compensated for losses 
or expenses actually incurred, donors should provide evi-
dence that compensation is indeed appropriate.
The document recognises that, in exceptional circum-
stances, Member States may opt to provide compensa-
tion in the form of a  fixed-rated scheme. In this case 
the conditions of “implementation must be provided for 
under national law, including the setting of an upper 
limit for compensation. If the upper limit is not speci-
fied by law, it should be established by an independent 
body set up in accordance with national law”.
A key element is that any reimbursement or compen-
sation should be disbursed in relation to living dona-
tions in so far as it is the donor whose losses are be-
ing reimbursed or compensated for. Reimbursement or 
compensation should never be connected to the dona-
tion as such.
The document then addresses the issue of payment 
for the provision of legitimate medical or related tech-
nical services. In this regard, the “Additional Protocol 
to the Convention on Human Rights and Biomedicine 
on transplantation of organs and tissues of human ori-
gin” explicitly allows for the payment of a justifiable fee 
for legitimate medical or related technical services ren-
dered in connection with transplantations [3]. The Ex-
planatory Report specifies that this could include “costs 
of retrieval, transport, preparation, preservation and 
storage (…), which may legitimately give rise to reason-
able remuneration” [8]. The Report also describes some 
of the technical processes that may legitimately give rise 
to justifiable costs, such as “sampling, testing, pasteuri-
sation, fractionation, purification, storage, culture and 
transport of related items”.
The Convention permits the sale of a medical device 
that incorporates human tissue that has undergone a 
manufacturing process provided the tissue used as the 
original material is not sold.
The issue of prohibiting financial gain also calls for 
clarification as to what constitutes a justifiable fee for 
the medical teams and processing services involved.
On this subject the Convention enjoins Member 
States to ensure that any arrangements for remuneration 
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or bonus payments envisaged in hospitals or donation 
centres in relation to medical services in connection with 
the donation of parts of the human body from both liv-
ing and deceased donors are comparable to those envis-
aged for other services provided by the medical team in 
the same hospital or donation facility or in similar insti-
tutions throughout that member state. This means that 
while overtime payments are permitted, bonus payments 
for work performed in relation to obtaining consent to 
donation from individuals or their families are not.
In the matter of processing fees for technical services 
connected with the donation of parts of the human 
body from either living or deceased donors, Member 
States are expected to ensure that these do not exceed 
the operational costs and are comparable among differ-
ent technical facilities, regardless of their legal status 
within a member state. Such fees may include the costs 
of procuring, testing, processing, storing and distribut-
ing human body parts, as well as costs related to the 
personnel involved in these procedures, transportation, 
infrastructure and administration, and the need to in-
vest in state-of-the-art equipment and processes to en-
sure the sustainability in the long term of all the proce-
dures and services involved, among others.
It is thus essential that great care be taken to ensure 
that donations of human cells, tissues and organs are 
voluntary and unpaid for and that legitimate forms of 
reimbursement or compensation do not translate into 
surreptitious forms of payment.
However, donations require the intervention of third 
parties, particularly of healthcare professionals, and 
the use of appropriate procedures, all of which can and 
must be paid for at the proper price. Here, too, there 
is a need for transparent regulations in order to prevent 
any form of financial gain.
The ISS attributes the greatest importance to these 
issues, particularly in consideration of the fact that it 
houses both the National Blood Centre and the Na-
tional Transplant Centre, two technical facilities of the 
Ministry of Health responsible respectively for the co-
ordination and technical-scientific control of all transfu-
sion medicine issues regulated by Italian and European 
legislation and for the organisation and management of 
the procedures for organ donation, procurement and 
transplants throughout Italy.
On the twentieth anniversary of the Convention the 
ISS is pleased to contribute to improving the implemen-
tation of one of its key underlying principles. The hu-
man body and its parts should never be reduced to the 
level of traded goods: this would reveal a lack of the 
respect due to the person and violate his dignity. 
CP is a member of the “Ad hoc working group on the 
prohibition of making a financial gain from the human 
body” of the Council of Europe.
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